| Summary: | 碩士 === 高雄醫學大學 === 醫學研究所 === 98 === Methicillin-resistant Staphylococcus aureus (MRSA) is difficult to cure in clinic. Thus, it’s important to find new therapies to against MRSA. We found one pure compound named tellimagrandin II, isolated from Trapa bispinosa. Previous study has showed Tellimagrandin I with the potential against MRSA. In this study, we investigated the effect and potential mechanisms of tellimagrandin II against MRSA. Using microdilution assay, tellimagrandin II reduced the minimum inhibitory concentration (MIC) of oxacillin in methicillin-resistant Staphylococcus aureus (MRSA). The time killing curve also showed tellimagrandin II had synergistic effect with oxacillin to kill MRSA. The mechanism indicated tellimagrandin II affected the function and production of penicillin binding protein production 2a (PBP2a); we found tellimagrandin II reduced mecA RNA and PBP2a protein expressions. Through BOCILIN FL (a florescent labeled penicillin) to realize the PBP binding activity of bacteria, we found the binding activity was reversed when tellimagrandin II treating MRSA. These results indicated that the major mechanism of tellimagrandin II to reverse the MRSA as MSSA was to reduce PBP2a production. Taken together, we expect tellimagrandin II would be a potential target on new therapeutic development on MRSA infections.
|
|---|
